- Home
- NVO vs JNJ Comparison
NVO vs JNJ Comparison
Compare NVO & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVO | JNJ |
|---|---|---|
| Founded | 1923 | 1886 |
| Country | Denmark | United States |
| Employees | 69500 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.4B | 542.4B |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | NVO | JNJ |
|---|---|---|
| Price | $47.66 | $254.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 20 |
| Target Price | $51.00 | ★ $238.20 |
| AVG Volume (30 Days) | ★ 11.9M | 7.7M |
| Earning Date | 05-06-2026 | 04-14-2026 |
| Dividend Yield | ★ 3.19% | 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.63 |
| Revenue Next Year | $3.70 | $7.43 |
| P/E Ratio | ★ $13.60 | $114.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.12 | $151.52 |
| 52 Week High | $71.80 | $251.71 |
Technical Indicators
Market Signals| Indicator | NVO | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 72.20 |
| Support Level | $47.52 | $233.83 |
| Resistance Level | $47.79 | N/A |
| Average True Range (ATR) | 1.32 | 5.13 |
| MACD | 0.47 | 1.78 |
| Stochastic Oscillator | 87.39 | 99.24 |
Price Performance
Historical ComparisonAbout NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.